The complex nature of the ocular drug delivery barrier presents a significant challenge to the effective administration of drugs, resulting in poor therapeutic outcomes. To address this issue, it is essential to investigate new drugs and alternative delivery routes and vehicles. One promising approach is the use of biodegradable formulations to develop potential ocular drug delivery technologies. These include hydrogels, biodegradable microneedles, implants, and polymeric nanocarriers such as liposomes, nanoparticles, nanosuspensions, nanomicelles, and nanoemulsions. The research in these areas is rapidly growing. In this review, we provide an overview of recent updates in biodegradable formulations for ocular drug delivery over the past decade. Additionally, we examine the clinical use of different biodegradable formulations in various ocular diseases. The aim of this review is to gain a deeper understanding of potential future trends in biodegradable ocular drug delivery systems and to raise awareness of their potential for practical clinical application as a means of providing new treatment options for ocular diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057390 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics15030734 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology of Consumer Product-Related Ocular Injuries in the Incarcerated Population.
Semin Ophthalmol
January 2025
Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, NJ, USA.
Purpose: To characterize the epidemiology of consumer product-related ocular injury in the United States (US) incarcerated population, and identify preventable causes.
Methods: The National Electronic Injury Surveillance System (NEISS) database was queried for cases of eye injury from 2014 to 2023. Incarcerated cases were identified using the keywords "prison", "jail", "inmate", and "incarcerate".
Generation of Retinal Ganglion Cells from Reprogrammed Keratocytes of Non-Glaucoma and Glaucoma Donors.
Curr Protoc
January 2025
Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana.
Human induced pluripotent stem cell (hiPSC)-based disease modeling can be successfully recapitulated to mimic disease characteristics across various human pathologies. Glaucoma, a progressive optic neuropathy, primarily affects the retinal ganglion cells (RGCs). While multiple groups have successfully generated RGCs from non-diseased hiPSCs, producing RGCs from glaucomatous human samples holds significant promise for understanding disease pathology by revealing patient-specific disease signatures.
View Article and Find Full Text PDFosteomyelitis in a dog.
Can Vet J
January 2025
Department of Comparative, Diagnostic, and Population Medicine, College of Veterinary Medicine, University of Florida, 2015 SW 16th Avenue, Gainesville, Florida 32608, USA (Whitman); Gulf Coast Veterinary Specialists, 8042 Katy Freeway, Houston, Texas 77024, USA (Wilson); Department of Small Animal Clinical Sciences, Texas A&M School of Veterinary Medicine and Biomedical Sciences, 4474 TAMU, College Station, Texas 77843, USA (Heseltine).
Canine systemic protothecosis is an uncommon disease caused by spp., which are saprophytic algae occurring ubiquitously in nature. Infection occurs most commonly in immunocompromised animals.
View Article and Find Full Text PDFMelanin-Binding-Based Discovery of Topically Instilled Carbonic Anhydrase Inhibitors for Targeted Delivery and Prolonged Action in the Eye.
Mol Pharm
January 2025
School of Pharmacy, University of Eastern Finland, Yliopistonranta 1 C, 70210 Kuopio, Finland.
Glaucoma is a vision-threatening disease that is currently treated with intraocular-pressure-reducing eyedrops that are instilled once or multiple times daily. Unfortunately, the treatment is associated with low patient adherence and suboptimal treatment outcomes. We developed carbonic anhydrase II inhibitors (CAI-II) for a prolonged reduction of intraocular pressure (IOP).
View Article and Find Full Text PDFRegistries in allergy: Structure, target groups, and key findings of allergy-focused registries in Germany.
Allergol Select
December 2024
Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
In allergology, clinical registries fill knowledge gaps of epidemiology, mechanisms of allergic diseases, and real-world treatment outcomes. Considering the continuous rise of allergic diseases worldwide, registries become increasingly important for the optimization and harmonization of patient care. In the current review, we present four ongoing allergy-focused registries initiated in Germany.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!